

MAJOR SHAREHOLDER ANNOUNCEMENT

September 12, 2012

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,845,307 shares of a nominal value of DKK 49,690,614, equivalent to 7.64% of Novozymes A/S' share capital and 3.07% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 16,235,029 B shares of a nominal value of DKK 32,470,058, equivalent to 4.995% of Novozymes share capital.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Investor relations:

Maarit Pokkinen

Tel. (direct): +45 4446 8682

Tel. (mobile): +45 3077 8682

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.